ANNX earnings: next report 2026-08-13, real EPS beat/miss history, analyst consensus Buy, P/E -4.29. Updated 2026-07-23.
Annexon (ANNX) Research Hub
Annexon (ANNX) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 3.94 USD (-9.84%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -4.29, market cap 0.62B. This hub links to the full technical, earnings and options research available for ANNX.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 3.94 USD (-9.84%) |
| 52-week range | 3.92 USD – 6.58 USD |
| Trend regime | Range |
| 14-day RSI | 19.8 (Oversold) |
| Trailing P/E | -4.29 |
| Market cap | 0.62B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-13 |
Available research for ANNX
Covered Call on ANNX: how it works, illustrative setup around the real 3.94 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on ANNX: how it works, illustrative setup around the real 3.94 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on ANNX: how it works, illustrative setup around the real 3.94 USD price, max profit/loss, breakeven and when to use it. Educational.
ANNX technical analysis: range, last 3.94 USD, RSI 19.8, 52w range 3.92 USD–6.58 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is ANNX in?
Annexon (ANNX) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is ANNX in an uptrend or downtrend?
As of 2026-09-11, ANNX is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is ANNX's trailing P/E ratio?
ANNX's trailing P/E is -4.29, with a market cap of 0.62B. See the earnings research page for full valuation detail.
When does ANNX next report earnings?
ANNX is next scheduled to report earnings on 2026-08-13, with a consensus EPS estimate of -0.23 USD.